GridAI Technologies Corp. (GRDX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GridAI Technologies Corp. (formerly Entero Therapeutics, Inc.) on January 7, 2026, covering the event date of December 31, 2025. The Company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol GRDX. The filing reports the completion of a significant asset disposition involving the unwinding of a prior merger transaction.
Key Financial Metrics
The filing does not provide specific historical revenue, profit, cash flow, or debt figures for the Company. Instead, it references unaudited pro forma financial information filed as Exhibit 99.1, which includes:
- Pro forma consolidated balance sheet as of September 30, 2025.
- Pro forma consolidated statements of operations for the nine months ended September 30, 2025, and the year ended December 31, 2024.
Specific numerical values for liquidity, margins, or debt are not contained within the text of this summary report.
Material Changes
The primary material change reported is the completion of a Rescission Agreement on December 31, 2025. Key details include:
- Transaction Completion: The Company transferred all issued and outstanding membership interests of ImmunogenX, LLC ("Immuno LLC") to the former shareholders of ImmunogenX, Inc. ("ImmunoCorp").
- Corporate Structure: Following the transaction, Immuno LLC is no longer a subsidiary of GridAI Technologies Corp., and the Company holds no interest in Immuno LLC.
- Historical Context: This action unwinds the Agreement and Plan of Merger dated March 13, 2024. The Rescission Agreement was originally filed on March 25, 2025, and amended on July 16, 2025, to include additional shareholder representations.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the disclosure of the completed disposition. The transaction is classified as a significant disposition under Item 2.01 of Form 8-K, necessitating the inclusion of pro forma financial data to reflect the Company's financial position absent the Immuno LLC subsidiary.
Investor Verification Checklist
- Pro Forma Financials: Review Exhibit 99.1 to understand the Company's financial position after the removal of Immuno LLC assets and liabilities.
- Shareholder Status: Verify the accreditation status of the Shareholders as required by the July 2025 Amendment to the Rescission Agreement.
- Asset Transfer: Confirm the final transfer of all membership interests in Immuno LLC to ensure no residual liabilities remain with GridAI.
- Historical Merger: Examine the original March 2024 Merger Agreement to understand the full scope of the unwound transaction.